The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t think it was enough.
Incyte Is Today’s Worst S&P 500 Stock. Here’s Why.
view original post
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t think it was enough.